289 related articles for article (PubMed ID: 23315072)
1. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
[TBL] [Abstract][Full Text] [Related]
2. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
Garcia-Hernandez Mde L; Hamada H; Reome JB; Misra SK; Tighe MP; Dutton RW
J Immunol; 2010 Apr; 184(8):4215-27. PubMed ID: 20237297
[TBL] [Abstract][Full Text] [Related]
4. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
5. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
6. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12.
Tajima M; Wakita D; Satoh T; Kitamura H; Nishimura T
Int Immunol; 2011 Dec; 23(12):751-9. PubMed ID: 22039016
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
8. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ- and IL-17-producing CD8
Ohkuri T; Kosaka A; Ikeura M; Salazar AM; Okada H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34193567
[TBL] [Abstract][Full Text] [Related]
10. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.
Lu Y; Hong B; Li H; Zheng Y; Zhang M; Wang S; Qian J; Yi Q
Proc Natl Acad Sci U S A; 2014 Feb; 111(6):2265-70. PubMed ID: 24469818
[TBL] [Abstract][Full Text] [Related]
12. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
Clin Immunol; 2001 Jan; 98(1):70-84. PubMed ID: 11141329
[TBL] [Abstract][Full Text] [Related]
13. Tc17 CD8 T cells: functional plasticity and subset diversity.
Yen HR; Harris TJ; Wada S; Grosso JF; Getnet D; Goldberg MV; Liang KL; Bruno TC; Pyle KJ; Chan SL; Anders RA; Trimble CL; Adler AJ; Lin TY; Pardoll DM; Huang CT; Drake CG
J Immunol; 2009 Dec; 183(11):7161-8. PubMed ID: 19917680
[TBL] [Abstract][Full Text] [Related]
14. Praziquantel facilitates IFN-γ-producing CD8+ T cells (Tc1) and IL-17-producing CD8+ T cells (Tc17) responses to DNA vaccination in mice.
Zou Q; Yao X; Feng J; Yin Z; Flavell R; Hu Y; Zheng G; Jin J; Kang Y; Wu B; Liang X; Feng C; Liu H; Li W; Wang X; Wen Y; Wang B
PLoS One; 2011; 6(10):e25525. PubMed ID: 21998665
[TBL] [Abstract][Full Text] [Related]
15. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
16. RORγ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment.
Liu X; Zawidzka EM; Li H; Lesch CA; Dunbar J; Bousley D; Zou W; Hu X; Carter LL
Cancer Immunol Res; 2019 Jul; 7(7):1054-1063. PubMed ID: 31064778
[TBL] [Abstract][Full Text] [Related]
17. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
18.
Flores-Santibáñez F; Cuadra B; Fernández D; Rosemblatt MV; Núñez S; Cruz P; Gálvez-Cancino F; Cárdenas JC; Lladser A; Rosemblatt M; Bono MR; Sauma D
Front Immunol; 2018; 9():209. PubMed ID: 29472932
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
20. The development of IL-17/IFN-γ-double producing CTLs from Tc17 cells is driven by epigenetic suppression of Socs3 gene promoter.
Satoh T; Tajima M; Wakita D; Kitamura H; Nishimura T
Eur J Immunol; 2012 Sep; 42(9):2329-42. PubMed ID: 22674086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
